Skye Bioscience (SKYE) Other Non-Current Assets (2014 - 2026)
Skye Bioscience (SKYE) posted quarterly Other Non-Current Assets of $35909.0 for Q1 2026, down 33.39% year-over-year from $53910.0 in Q1 2025, and down 33.39% quarter-over-quarter from $53910.0 in Q4 2025.
Skye Bioscience (SKYE) Other Non-Current Assets (2014 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Other Non-Current Assets for 10 consecutive years, with $35909.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 33.39% year-over-year to $35909.0; the TTM figure through Mar 2026 stood at $35909.0 (down 33.39% YoY), while the FY2025 annual figure was $53910.0, changed 0.0% from the prior year.
- Other Non-Current Assets eased to $35909.0 in Q1 2026 per SKYE's latest filing, from $53910.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $53910.0 in Q4 2024 and bottomed at $8309.0 in Q1 2022.
- Historically, Other Non-Current Assets has averaged $26549.4 across 5 years, with a median of $8309.0 in 2022.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets jumped 548.81% — and 2026, when it plunged 33.39%.
- Skye Bioscience's Other Non-Current Assets stood at $8309.0 in 2022, then changed by 0.0% to $8309.0 in 2023, then surged by 548.81% to $53910.0 in 2024, then changed by 0.0% to $53910.0 in 2025, then plunged by 33.39% to $35909.0 in 2026.
- Business Quant data shows SKYE's Other Non-Current Assets at $35909.0 in Q1 2026, $53910.0 in Q4 2025, and $53910.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Skye Bioscience | 10.86 Mn | 10.86 Mn | - | 8,309.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35,909.00 |
| Dec 31, 2025 | 53,910.00 |
| Sep 30, 2025 | 53,910.00 |
| Jun 30, 2025 | 53,910.00 |
| Mar 31, 2025 | 53,910.00 |
| Dec 31, 2024 | 53,910.00 |
| Sep 30, 2024 | 26,310.00 |
| Jun 30, 2024 | 8,309.00 |
| Mar 31, 2024 | 8,309.00 |
| Dec 31, 2023 | 8,309.00 |
| Sep 30, 2023 | 8,309.00 |
| Dec 31, 2022 | 8,309.00 |
| Sep 30, 2022 | 8,309.00 |
| Jun 30, 2022 | 8,309.00 |
| Mar 31, 2022 | 8,309.00 |
| Sep 30, 2021 | 8,309.00 |
| Sep 30, 2017 | 34,290.00 |
| Jun 30, 2017 | 34,290.00 |
| Mar 31, 2017 | 34,290.00 |
| Dec 31, 2016 | 34,290.00 |